

the receipt of a sufficient number of applications of high scientific merit and availability of funds. Although this program is provided for in the financial plans of the NIDDK, awards pursuant to this RFA are contingent upon the availability of funds and the receipt of a sufficient number of applications of outstanding scientific and technical merit.

Contact: The letter of intent is to be sent to: Chief, Review Branch Division of Extramural Activities National Institute of Diabetes, Digestive, and Kidney Diseases 6707 Democracy Boulevard Room 752, MSC 5452 Bethesda, Maryland 20892-5452 Bethesda, Maryland 20827 (for courier service) Telephone: (301) 594-8897 Fax: (301) 480-3505 Email: fc15y@nih.gov The research grant application form PHS 398 (rev. 4/98) at <http://grants.nih.gov/grants/funding/phs398/phs398.html> is to be used in applying for these grants. These forms are available at most institutional offices of sponsored research and from the Division of Extramural Outreach and Information Resources, National Institutes of Health, 6701 Rockledge Drive, MSC 7910, Bethesda, MD 20892-7910, telephone 301/435-0714, email: GrantsInfo@nih.gov.

Deadline: Applicant Information Forum Date: October 8, 2001. Letter of Intent Receipt Date: February 15, 2002 Application Receipt Date: March 15, 2002.

TREATMENT OF HAART-ASSOCIATED METABOLIC CHANGES IN PATIENTS WITH HIV INFECTION: DK-02-006

Purpose: The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Heart, Lung and Blood Institute (NHLBI) seek applications to develop and test strategies for treating the metabolic complications associated with anti-retroviral drug therapy in patients with HIV infection. In recent years, the advent of highly active anti-retroviral therapy (HAART) has dramatically improved the survival of patients infected with HIV. Despite the benefits of the new anti-retroviral therapies, HAART has been associated with a variety of metabolic complications – including dyslipidemia, insulin resistance and abnormal distribution of body fat (lipodystrophy) – all of which are major risk factors for the development of other serious diseases, such as diabetes and cardiovascular disease. Of particular concern for many patients has been the problem of lipodystrophy, characterized by increased deposition of fat in the abdomen and trunk, and/or loss of fat in the face and extremities. Distress over these often disfiguring changes has caused some patients to stop taking anti-viral medications. This RFA solicits clinical studies to 1) test the efficacy, in patients infected with HIV, of agents currently approved for the treatment of dyslipidemia, insulin resistance or diabetes, and osteoporosis, and 2) develop and test novel treatment

approaches to HAART-associated metabolic changes, including lipodystrophy.

Term/Amount: For fiscal year 2002, the NIDDK intends to commit approximately \$2 million and the NHLBI intends to commit approximately \$500,000 to fund 4-10 grants in response to this RFA. An applicant may request a project period of up to 5 years for R01s and up to two years for R21s. Because the nature and scope of the research proposed may vary, it is anticipated that the size of each award will also vary. Although the financial plans of the NIDDK and the NHLBI provide support for this program, awards pursuant to this RFA are contingent upon the availability of funds and the receipt of a sufficient number of applications of outstanding scientific and technical merit.

Contact: The letter of intent is to be sent to: Chief, Review Branch Division of Extramural Activities, NIDDK 6707 Democracy Boulevard, Rm. 752 MSC 5452 Bethesda, MD 20892-5452 (for express/courier service: Bethesda, MD 20817) Telephone: (301) 594-8885 FAX: (301) 480-3505 The PHS 398 research grant application instructions and forms (rev. 5/2001) at <http://grants.nih.gov/grants/funding/phs398/phs398.pdf> is to be used in applying for these grants. This version of PHS 398 is available in an interactive, searchable PDF format. Although applicants are strongly encouraged to begin using the 5/2001 revision of the PHS 398 as soon as possible, the NIH will continue to accept applications prepared using the 4/1998 revision until January 9, 2002. Beginning January 10, 2002, however, the NIH will return applications that are not submitted on the 5/2001 version. For further assistance contact GrantsInfo, Telephone 301/435-0714, Email: GrantsInfo@nih.gov.

Deadline: Letter of Intent Receipt Date: February 21, 2002. Application Receipt Date: March 21, 2002.

MULTIDISCIPLINARY CLINICAL RESEARCH CENTERS FOR ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES: AR-01-006

Purpose: The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) invites applications for a new program of Multidisciplinary Clinical Research Centers (MCRCs) in arthritis and/or musculoskeletal disorders and/or skin diseases. The goals of this new program are to prevent disease and to assess and improve outcomes for patients with arthritis and other rheumatic diseases; musculoskeletal disorders including orthopaedic disorders, bone diseases and muscle diseases; and skin diseases. For a comprehensive listing of the disease areas covered in the NIAMS extramural programs, please see <http://www.nih.gov/niams/grants/gen2.html> Each MCRC will be organized around a methodology core and will be expected to include a minimum of three highly

meritorious projects encompassing clinical research drawing from different disciplines. The methodology core will be the foundation of the center, providing key support for development and implementation of clinical projects. Each project must address a critical issue that directly involves prevention, assessment and/or outcomes for patients with one or more of the many chronic diseases within the mission of the NIAMS.

Term/Amount: The NIAMS intends to commit approximately \$3.6 million in FY 2003 to fund up to three applications responding to this RFA. The applicant should request a project period of five years. The direct costs requested cannot exceed \$800,000 each year (exclusive of facilities and administrative costs of subcontracts with collaborating organizations). Although the financial plans of the NIAMS provide support for this program, awards pursuant to this RFA and future RFAs are contingent upon the availability of funds and the receipt of a sufficient number of meritorious applications. This RFA is the final

of three RFAs to establish the new NIAMS MCRC program. Previous RFAs were AR-00-001 for FY 2001 funding and AR-00-004 for FY 2002 funding.

Contact: The letter of intent is to be sent to Dr. Julia B. Freeman Centers Program, EP National Institute of Arthritis and Musculoskeletal and Skin Diseases Natcher Building, Room 5AS.19F MSC 6500 Bethesda, MD 20892-6500 Bethesda, MD 20814 (for express/courier service) Telephone: (301) 594-5052 FAX: (301) 480-4543 Email: Julia_B_Freeman@nih.gov The research grant application form PHS 398 (rev. 4/98) is to be used in applying for these grants. These forms are available at most institutional offices of sponsored research and may be obtained from the Division of Extramural Outreach and Information Resources, National Institutes of Health, 6701 Rockledge Drive, MSC 7910, Bethesda, MD 20892-7910, telephone 301/435-0714, email: grantsinfo@nih.gov.

Deadline: Letter of Intent Receipt Date: February 1, 2002. Application Receipt Date: March 12, 2002.